Dapsone as corticosteroid-sparing therapy for Sweet syndrome

Hrin, Matthew L.; Feldman, Steven R.; Huang, William W.

doi:10.1016/j.jaad.2021.02.067

Cited by 7 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an 11-patient retrospective study, Hrin et al described dapsone, at a median daily dosage of 100 mg for a median duration of 13 months, to result in an 82% response rate. However, two patients experienced myelosuppression, warranting treatment cessation [160].…”

Section: Therapeutic Optionsmentioning

confidence: 99%

New Practical Aspects of Sweet Syndrome

et al. 2022

View full text Add to dashboard Cite

Sweet syndrome (SS), or acute febrile neutrophilic dermatosis, is an inflammatory, non-infectious skin reaction characterized clinically by tender, erythematous papules/plaques/pustules/nodules commonly appearing on the upper limbs, trunk, and head and neck; histologically, SS is characterized by dense neutrophilic infiltrate in the dermis. SS is accompanied by fever; an elevation of inflammatory markers (e.g., erythrocyte sedimentation rate, C reactive protein) in serum may also be observed. Although most cases of SS are idiopathic, SS also occurs in the setting of malignancy or following administration of an associated drug. SS has also been reported in association with pregnancy and a burgeoning list of infectious (most commonly upper respiratory tract infections) and inflammatory diseases; likewise, the litany of possible iatrogenic triggers has also grown. Over the past several years, a wider spectrum of SS presentation has been realized, with several reports highlighting novel clinical and histological variants. Corticosteroids continue to be efficacious first-line therapy for the majority of patients with SS, although novel steroid-sparing agents have been recently added to the therapeutic armamentarium against refractory SS. New mechanisms of SS induction have also been recognized, although the precise etiology of SS still remains elusive. Here, we catalogue the various clinical and histological presentations of SS, summarize recently reported disease associations and iatrogenic triggers, and review treatment options. We also attempt to frame the findings of this review in the context of established and emerging paradigms of SS pathogenesis.

show abstract

Section: Therapeutic Optionsmentioning

confidence: 99%

New Practical Aspects of Sweet Syndrome

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Initial responses (median 1.5 months) occurred slightly slower than both SCSs (0.25, 0.5 months) and dapsone for Sweet syndrome (1 month). 4,5 While eight patients initiated MTX with concomitant prednisone, all MTX responders tapered off prednisone within a median 1.5 months, and most responders either continued to improve (4 subsequently completely cleared) or maintained their responses (2) after tapering. Three responders flared (2 during MTX therapy [simultaneously with Crohn’s flares], one 14 months after MTX cessation).…”

mentioning

confidence: 99%

Evaluation of Methotrexate in the Management of Sweet Syndrome

et al. 2022

Self Cite

View full text Add to dashboard Cite

Neutrophilic Dermatoses: a Clinical Update

Weiss

Leung

et al. 2022

Curr Derm Rep

View full text Add to dashboard Cite

Purpose of Review Neutrophilic dermatoses are defined by the presence of a sterile neutrophilic infiltrate on histopathology. This review focuses on the pathogenesis, epidemiology, clinicopathological features, diagnosis, and management of four disorders: Sweet syndrome, pyoderma gangrenosum, Behçet syndrome, and neutrophilic eccrine hidradenitis.Recent Findings Recent studies have provided insight into the complex pathogenesis of neutrophilic dermatoses. Evidence supports an intricate interplay of abnormal neutrophil function and inflammasome activation, malignant transformation into dermal infiltrating neutrophils, and genetic predisposition. Summary Neutrophilic dermatoses have diverse cutaneous and extracutaneous manifestations and may be associated with significant morbidity and mortality. Common underlying associations include infectious, inflammatory, and neoplastic disorders, as well as drug reactions. Emerging diagnostic and therapeutic frameworks identify an expanding role for biologic and targeted anti-inflammatory therapies. KeywordsAcute febrile neutrophilic dermatosis • Behçet disease • Neutrophilic dermatosis • Neutrophilic eccrine hidradenitis • Pyoderma gangrenosum • Sweet syndrome This article is part of the Topical Collection on Hospital-Based Dermatology

show abstract

Dapsone as corticosteroid-sparing therapy for Sweet syndrome

Cited by 7 publications

References 6 publications

New Practical Aspects of Sweet Syndrome

New Practical Aspects of Sweet Syndrome

Evaluation of Methotrexate in the Management of Sweet Syndrome

Neutrophilic Dermatoses: a Clinical Update

Contact Info

Product

Resources

About